Big Cypress Acquisition Corp. (BCYP)
| Market Cap | 148.96M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 14.79M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 115,691 |
| Open | 10.10 |
| Previous Close | 10.07 |
| Day's Range | 10.07 - 10.10 |
| 52-Week Range | 9.70 - 10.75 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About BCYP
Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.
News
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 ...
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #ACTG--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-po...
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Bioth...
MIAMI, Sept. 23, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, toda...
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability...
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BARDA--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-p...
SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Se...
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-po...
SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-po...
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2...
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-po...
Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics
MIAMI, July 15, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today reported that Eddie J. Sulliva...
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-hum...
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-...
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #COVID19--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high...
Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Bus...
MIAMI, July 7, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today announced the confidential subm...
SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-hum...
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antib...
SIOUX FALLS, S.D. & MIAMI--(BUSINESS WIRE)-- #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces targeted, high potency, fully-...
Big Cypress Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, which Includes Full Exercise...
MIAMI, FL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Big Cypress Acquisition Corp. (the "Company") announced today that it closed its initial public offering of 11,500,000 units, which includes the full exercis...
Big Cypress Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
MIAMI, FL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Big Cypress Acquisition Corp. (the "Company") announced today the pricing of its initial public offering of 10,000,000 units at a price of $10.00 per unit. T...
Life sciences SPAC Big Cypress Acquisition raises deal size by 33% ahead of $100 million IPO
Big Cypress Acquisition, a blank check company targeting life science businesses in the US and Israel, raised the proposed deal size for its upcoming IPO on Monday. The Miami Beach, FL-based company now...
Life sciences SPAC Big Cypress Acquisition files for a $75 million IPO
Big Cypress Acquisition, a blank check company targeting life science businesses in the US and Israel, filed on Monday with the SEC to raise up to $75 million in an initial public offering.
Big Cypress Acquisition IPO Registration Document (S-1)
Big Cypress Acquisition Corp. has filed to go public with an IPO on the New York Stock Exchange (NYSE).